High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  D'Angelo, Daniela ^a   Mussnich, Paula ^a   Rosa, Roberta ^a   Bianco, Roberto ^a   Tortora, Giampaolo ^b   Fusco, Alfredo ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Chemoresistance; Colon cancer; HMGA1; Thyroid cancer

Indexed keywords

CETUXIMAB; DOXORUBICIN; HIGH MOBILITY GROUP A1 PROTEIN; NUCLEIC ACID BINDING PROTEIN; PANOBINOSTAT; PROTEIN KINASE B; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CASPASE; HIGH MOBILITY GROUP A PROTEIN;

ARTICLE; CANCER CELL; CELL SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID CARCINOMA; APOPTOSIS; COLONIC NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; THYROID NEOPLASMS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL SURVIVAL; COLONIC NEOPLASMS; DNA DAMAGE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE SILENCING; HMGA PROTEINS; HUMANS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 84964313241     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-851     Document Type: Article

References (20)

1. Luqmani YA: Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005, 14(Suppl 1):35-48.
2. Roberti A, La Sala D, Cinti C: Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol 2006, 207:571-581.
3. Fusco A, Fedele M: Roles of HMGA proteins in cancer. Nat Rev Cancer 2007, 7:899-910.
4. Fedele M, Fusco A: HMGA and cancer. Biochim Biophys Acta 2010, 1799:48-54.
5. Summer H, Li O, Bao Q, Zhan L, Peter S, Sathiyanathan P, Henderson D, Klonisch T, Goodman SD, Dröge P: HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy. Nucleic Acids Res 2009, 37:4371-4384.
6. Liau SS, Wang E: HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res 2008, 1;14(5):1470-1477.
7. Palmieri D, Valentino T, D'Angelo D, De Martino I, Postiglione I, Pacelli R, Croce CM, Fedele M, Fusco A: HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents. Oncogene 2011, 7;30(27):3024-3035.
8. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360(14):1408-1417.
9. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G: Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to anti-epidermal growth factor receptor therapy. Clin Cancer Res 2004, 10:784-793.
10. Pierantoni GM, Fedele M, Pentimalli F, Benvenuto G, Pero R, Viglietto G, Santoro M, Chiariotti L, Fusco A: High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene 2001, 20(43):6132-6141.
11. Livak KJ, Schmittgen TD: Analysis of relative gene expressiondata using real-time quantitative PCR and the 2(Delta DeltaC(T)) method. Methods 2001, 25(4):402-408.
12. Haugen BR: Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999, 16:34-41.
13. Szumiel I: Epidermal growth factor receptor and DNA double strand break repair: the cell's self-defence. Cell Signal 2006, 10:1537-1548.
14. Kriegs M1, Kasten-Pisula U, Rieckmann T, Holst K, Saker J, Dahm-Daphi J, Dikomey E: The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. DNA Repair (Amst) 2010, 9(8):889-897.
15. Scala S, Portella G, Fedele M, Chiappetta G, Fusco A: Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci U S A 2000, 97(8):4256-4261.
16. Granville CA, Memmott RM, Gills JJ, Dennis PA: Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006, 12:679-689.
17. Valerie K, Yacoub A, Hagan MP, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P: Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 2007, 6:789-801.
18. Viniegra JG, Martínez N, Modirassari P, Hernández Losa J, Parada Cobo C, Sánchez-Arévalo Lobo VJ, Aceves Luquero CI, Alvarez-Vallina L, Ramón y Cajal S, Rojas JM, Sánchez-Prieto R: Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem 2005, 280:4029-4036.
19. Lee MJ1, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, Yaffe MB: Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012, 149(4):780-794.
20. Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De Falco S, Melisi D, Benelli R, Albini A, Ryan A, Ciardiello F, Tortora G: Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res 2008, 14(16):5069-5080.